Cargando…

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib

Tyrosine kinase inhibitors revolutionized cancer therapy but still evoke strong adverse effects that can dramatically reduce patients’ quality of life. One possibility to enhance drug safety is the exploitation of prodrug strategies to selectively activate a drug inside the tumor tissue. In this stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bielec, Bjoern, Poetsch, Isabella, Ahmed, Esra, Heffeter, Petra, Keppler, Bernhard K., Kowol, Christian R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179202/ https://www.ncbi.nlm.nih.gov/pubmed/32143435 http://dx.doi.org/10.3390/molecules25051149

Ejemplares similares

Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
por: Kastner, Alexander, et al.
Publicado: (2023)

Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs
por: Mathuber, Marlene, et al.
Publicado: (2020)

Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands
por: Fronik, Philipp, et al.
Publicado: (2021)

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
por: Fronik, Philipp, et al.
Publicado: (2022)

Synthesis, Characterization and in vitro Studies of a Cathepsin B‐Cleavable Prodrug of the VEGFR Inhibitor Sunitinib
por: Karnthaler‐Benbakka, Claudia, et al.
Publicado: (2018)

A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt(IV) Complexes under Physiological Conditions
por: Kastner, Alexander, et al.
Publicado: (2019)

An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo
por: Mayr, Josef, et al.
Publicado: (2017)

Influence of the Fatty Acid Metabolism on the Mode of Action of a Cisplatin(IV) Complex with Phenylbutyrate as Axial Ligands
por: Mendrina, Theresa, et al.
Publicado: (2023)

Liposomal formulations of anticancer copper(ii) thiosemicarbazone complexes
por: Mathuber, Marlene, et al.
Publicado: (2021)

Development of a cobalt(iii)-based ponatinib prodrug system
por: Mathuber, Marlene, et al.
Publicado: (2021)

Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
por: Pelivan, Karla, et al.
Publicado: (2018)

Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo
por: Schueffl, Hemma, et al.
Publicado: (2021)

Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report
por: ZHANG, NA, et al.
Publicado: (2014)

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
por: Nehoff, Hayley, et al.
Publicado: (2015)

P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape
por: Sun, Huiyong, et al.
Publicado: (2014)

Structure elucidation and quantification of the reduction products of anticancer Pt(iv) prodrugs by electrochemistry/mass spectrometry (EC-MS)
por: Frensemeier, L. M., et al.
Publicado: (2018)

Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling
por: Miklos, Walter, et al.
Publicado: (2016)

The thiosemicarbazone Me(2)NNMe(2) induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition
por: Hager, Sonja, et al.
Publicado: (2018)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones
por: Heffeter, Petra, et al.
Publicado: (2012)

Human serum albumin as a copper source for anticancer thiosemicarbazones
por: Schaier, Martin, et al.
Publicado: (2023)

Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment
por: Oddone, Natalia, et al.
Publicado: (2020)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
por: Wang, Wenxian, et al.
Publicado: (2016)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
por: Iyer, Sudarshan R, et al.
Publicado: (2023)

Impact of Stepwise NH(2)-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention
por: Kowol, Christian R., et al.
Publicado: (2016)

Anticancer effect of (S)-crizotinib on osteosarcoma cells by targeting MTH1 and activating reactive oxygen species
por: Qing, Xiangcheng, et al.
Publicado: (2018)

Crizotinib for ROS1‐rearranged lung cancer and pulmonary tumor thrombotic microangiopathy under venoarterial extracorporeal membrane oxygenation
por: Aoyama, Daisetsu, et al.
Publicado: (2022)

Synthesis and Evaluation of Reactive Oxygen Species Sensitive Prodrugs of a NAMPT Inhibitor FK866
por: Xu, Zili, et al.
Publicado: (2022)

Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report
por: Yang, Guangdie, et al.
Publicado: (2021)

EGFR-targeting peptide-coupled platinum(IV) complexes
por: Mayr, Josef, et al.
Publicado: (2017)

Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
por: Gu, Ting-Lei, et al.
Publicado: (2011)

Protamine-2 Deficiency Initiates a Reactive Oxygen Species (ROS)-Mediated Destruction Cascade during Epididymal Sperm Maturation in Mice
por: Schneider, Simon, et al.
Publicado: (2020)

Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux
por: Bormio Nunes, Julia H., et al.
Publicado: (2020)

Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
por: Begum, Parvin, et al.
Publicado: (2022)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib
por: Huang, Qiang, et al.
Publicado: (2015)

Reactive oxygen species activated by mitochondria-specific camptothecin prodrug for enhanced chemotherapy
por: Guo, Zhaopei, et al.
Publicado: (2022)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
por: Ryu, Woo Kyung, et al.
Publicado: (2022)

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib
por: He, Yueming, et al.
Publicado: (2019)

ROS-Responsive and pH-Sensitive Aminothiols Dual-Prodrug for Radiation Enteritis
por: Chen, Yuanfang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mhbm0jb2ov2p0j87h6a98ci6hj